Analysts' Top 5 Price Targets of August 25, 2025
Reading Time: 4 minutes
Ionis Pharmaceuticals [US4622221004] Wells Fargo reiterates Overweight rating and raises the price target from $77 to $82 (92% upside potential) The background of this decision is the recent FDA approval of Dawnzera ( Donidalorsen ), a medication for the prophylaxis of hereditary angioedema (HAE) in patients aged 12 years and older. Dawnzera features a particularly patient-friendly dosing regimen. The dosing advantages could lead to a "switch-driven” market f unction, in which many patients switch from Takhzyro (from competitor...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
